Abstract: 【Abstract】 This review summarizes the contribution of interleukin-17 （IL-17） to the susceptibility to mucocutaneous fungal infections, and superficial fungal infections associated with IL-17-targeting biological agents, such as secukinumab, ixekizumab, brodalumab, bimekizumab and ustekinumab, in the treatment of psoriasis. The superficial fungal infections related to the treatment with IL-17 monoclonal antibody agents are usually mild or moderate, and most of them are limited, with a good response to anti-fungal therapy. In addition, this review introduces clinical evaluation, monitoring and treatment of related superficial fungal infections, and provides a basis for safe clinical use of IL-17-targeting biologics.

Key words: Psoriasis, Biological agents, Interleukin-17, Drug toxicity, Candidiasis, cutaneous